Modified CAR-T Therapy Shows Potential for Treating Myasthenia Gravis, a Nervous System Autoimmune Disorders
Researchers have discovered that a modified version of CAR-T therapy, a revolutionary immunotherapy primarily used for treating advanced blood cancers, could potentially be repurposed to address myasthenia gravis, an autoimmune disorder affecting the nervous system. The adapted CAR-T therapy, which stands for chimeric antigen receptor T-cell, demonstrated the potential for longer-lasting alleviation of myasthenia gravis symptoms and was well-tolerated by patients without significant adverse effects. The study, published in The Lancet Neurology, received support from a small business grant provided by the National Institute of Neurological Disorders and Stroke (NINDS), a division of the National Institutes of Health, and was sponsored by Cartesian Therapeutics in Gaithersburg, Maryland. Versatility of Immunotherapies Dr. Emily Caporello, director of the NINDS Small Business Program, highlighted the versatility of immunotherapies in circumstances where limited or no treatment optio...